Pfizer (PFE) – Press Releases
-
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
-
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
-
ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager
-
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
-
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
-
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
-
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities
-
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
-
Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
-
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
-
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
-
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
-
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
-
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
-
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
-
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
-
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
-
ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
-
ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
-
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
-
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
-
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
-
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
-
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
-
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
-
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
-
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
-
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
-
Pfizer Declares First-Quarter 2024 Dividend
-
Pfizer Completes Acquisition of Seagen
-
Pfizer Provides Full-Year 2024 Guidance
-
Update: Annual Changes to the Nasdaq-100® Index
-
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
-
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
-
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
-
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
-
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
-
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
-
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
-
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
-
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
Back to PFE Stock Lookup
